Cambridge Healthtech Institute’s

Bispecific Engineering & Therapeutics

January 13, 2025

New and groundbreaking strides have been made in the field of bi and multispecific antibodies. Join us for Cambridge Healthtech Institute's Bispecific Engineering and Therapeutics symposium. Here we discuss exciting advancements with bispecific antibodies, multispecific antibodies, T cell engagers, combination therapies, conditionally active antibodies, and antibody drug conjugates in the context of bi and multispecific antibodies. Uncover cutting-edge research and findings in heme malignancies, solid tumors, and indications beyond oncology. Register now to learn about the innovative technologies, techniques, and tools that are transforming bi and multispecific therapeutics.

Design and Engineering

Optimizing bi and multispecific antibody design for internalization
Modulating linker binding distances
Optimizing ADC payload conjugation to bispecific antibodies
Combination therapies
ML/AI applications for bi and multispecific engineering
Engineering bi and multispecific antibodies with reduced cytokine release syndrome (CRS) risk
Next-gen T cell engagers
- strategies for solid tumor infiltration

Conditionally Active Antibodies

Masking approaches
Alternative approaches to masking
pH-dependent antibodies
Induced proximity-based approaches

Expanding Therapeutic Horizons Beyond Oncology

Applications of bi and multispecific antibodies to:
- Inflammation
- Neurodegenerative diseases
- Auto-immune diseases
- Infectious diseases

The deadline for priority consideration is June 28, 2024.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: